The prevention of ovarian hyperstimulation syndrome

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 103, Issue 8, 1996, Pages 740-746

  Mathur, R S ^a   Joels, L A ^a   Akande, A V ^a   Jenkins, J M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CAPTOPRIL; CHLORPHENIRAMINE MALEATE; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN ALBUMIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ANOVULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; ECHOGRAPHY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GAMETE INTRAFALLOPIAN TRANSFER; HIGH RISK PATIENT; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY DISEASE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

CHORIONIC GONADOTROPIN; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; OVARIAN HYPERSTIMULATION SYNDROME; RISK FACTORS;

EID: 0029744447     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1996.tb09867.x     Document Type: Review

References (64)

1. Rizk B. Ovarian hyperstimulation syndrome. In: Studd, JWW, editors. Progress in Obstetrics and Gynaecology Vol 11. London: Churchill Livingstone 1995: 311–349.
2. Soliman S, Daya S, Collins J, Hughes EG. The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 1994; 61:1068–1076.
3. Mathur RS, Joels LA, Jenkins JM. Ovarian hyperstimulation may be more likely if multiple pregnancy follows assisted conception. Acta Genet MedGemellol 1996; 44:145–147.
4. Schmidt LL, Asch RJ, Frederick JL, Rojas FJ, Stone SC, Balmaceda JP. Predictive value of a single beta human chorionic gonadotropin level in pregnancies achieved by assisted reproduction techniques. Fertil Steril 1994; 62:333–338.
5. Pride SM, Yuen BH, Moon YS. Clinical, endocrinologic and intraovarian prostaglandin F responses to H-l receptor blockade in the ovarian hyperstimulation syndrome: studies in the rabbit model. Am J Obstet Gynecol 1984; 148:670–674.
6. Navot D, Margalioth EJ, Laufer N et al. Direct correlation between plasma renin activity and the severity of ovarian hyperstimulation syndrome. Ferril Steril 1987; 48:57–61.
7. Balasch J, Arroyo V, Carmona F, Llach J, Jimenez W, Pare JCV, Vanrell JA. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilatation. Fertil Steril 1991; 56:1077–1083.
8. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 1992; 9:429–438.
9. Bodis J, Tinneberg H-R, Hanf V, Torok A, Gros M. Prophylaxis of ovarian hyperstimulation syndrome (letter). Hum Reprod 1992; 7:1181.
10. Delvigne A, Demoulin A, Smitz J et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multi-centric study. I. Clinical and biologic features. Hum Reprod 1993; 8:1353–1360.
11. Salat-Baroux J, Alvarez S, Antoine JM et al. Treatment of hyperstimulation during in-vitro fertilization. Hum Reprod 1990; 5:36–39.
12. MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992; 7:597–600.
13. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58:249–261.
14. Navot D, Relou A, Birkenfield A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159:210–215.
15. Lewis CG, Wurness GM, Wang X, Matthews CD. Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normally cycling women. Fertil Steril 1990; 53:1097–1099.
16. Delvigne A, Dubois M, Battheu B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multi-centric study. 11. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8:1361–1366.
17. Asch RH, Li H, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991; 6:1395–1399.
18. Schenker JG. Prevention and treatment of ovarian hyperstimulation syndrome. Hum Reprod 1993; 8:653–659.
19. Golan A, Herman A, Soffer Y, Bukovsky I, Ron-El R. Ultrasonic control without hormone determination for ovulation induction in in-vitro fertilisation/embryo transfer with gonadotropin releasing hormone analogue and human menopausal gonado-tropins. Hum Reprod 1994; 9:1631–1633.
20. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an Update Review. Obstet Gynecol Surv 1989; 44:430–441.
21. Delvigne A, Vandromme J, Barlow P, Lejeunne B, Leroy F. Are there predictive criteria of complicated ovarian hyperstimulation syndrome in IVF Hum Reprod 1991; 6:959–962.
22. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod 1995; 10:811–814.
23. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990; 53:502–509.
24. Giirgan T, Yarali H, Urman B. Laparoscopic treatment of polycystic ovarian disease. Hum Reprod 1994; 9:573–577.
25. Shoham Z, Patel A, Jacobs SH. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of Durified follicle-stimulating hormone. Fertil Steril 1991: 55:lO1l–1056.
26. Dale PO, Tanbo T, Haug E, Abyholm T. Polycystic ovary syndrome: low dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients. Hum Reprod 1992; 7:1085–1089.
27. Mordel N, Schenker JG. Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation in assisted reproduction. Hum Reprod 1993; 8:2009–2014.
28. Shoham Z, Schachter M, Loumaye E, Weissman A, MacNamee M, Insler V. The luteinizing hormone surge–the final stage in ovulation induction: modem aspects of ovulation triggering. Fertil Steril 1995; 64:237–251.
29. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH analogues for IVF and related procedures. Hum Reprod 1992; 7:320–327.
30. Tanbo T, Dale PO, Kjekshus E, Haug E, Abyholm T. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovary syndrome. Fertil Steril 1990; 53:798–803.
31. Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 1992; I: 213–217.
32. Emperaire JC, Rae A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 1991; 6:506–510.
33. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Merab 1990; 71:918–922.
34. Imoedemhe DAG, Chan RCW, Sigue AB, Pacpaco ELA, Olazo AB. A new approach to the management of patients at risk of ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 1991; 6:1088–1091.
35. Shalev E, Geslevich Y, Ben-Ami M. Induction of pre-ovulatory LH surge by gonadotropin-releasing hormone agonist therapy for women at risk for developing ovarian hyperstimulation syndrome. Hum Reprod 1994; 9: 417–419.
36. Reissmann Th, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of leuteinising hormone-releasing antagonists in the treatment of infertility: an overview. Hum Reprod 1995: 10:1974–1981.
37. Gonen Y, Powell WA, Casper RF. Effects of follicular aspiration on hormonal parameters in patients undergoing ovarian stimulation. Hum Reprod 1991; 61:356–358.
38. Fakih H, Bello S. Ovarian cyst aspiration: a therapeutic approach to ovarian hyperstimulation syndrome. Fertil Steril 1992; 58:829–832.
39. Aboulghar MA, Mansour RT, Serour GI, Elattar I, Amin Y. Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome. J Assist Reprod Genet 1992; 9:238–243.
40. Mills MS, Eddowes HA, Cahill DJ et al. A prospective controlled study of in-vitro fertilization, gamete intra-fallopian transfer and intra-uterine insemination combined with superovulation. Hum Reprod 1992; 7:490–494.
41. Gratton RJ, Nisker JA, Daniel S et al. An aggressive philosophy in controlled ovarian stimulation cycles increases pregnancy rates. Hum Reprod 1993; 8:528–531.
42. Nisker J, Tummon I, Daniel S, Kaplan B, Yuzpe A. Conversion of cycles involving ovarian hyperstimulation with intra-uterine insemination to in-vitro fertilization. Hum Reprod 1994; 9:406–408.
43. Wada I, Matson PL, Troup SA, Morroll DR, Hunt L, Leiberman BA. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition Br J Obstet Gynaecol 1993; 100:265–269.
44. Tiitinen A, Husa LM, Tuppala M, Simberg N, Seppala M. The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102:326–329.
45. Jenkins JM, Mathur RS, Cooke ID. The management of severe ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102:2–5.
46. Araujo, E Jr, Bernardini, L, Frederick JL, Asch RH, Balmaceda JP. Prospective randomised comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J Assist Reprod Genet 1994; 11:74–78.
47. Buvat J, Marcolin G, Guittard C, Herbaut JH, Louvet AL, Dehaene J-L. Luteal support after luteinising hormone-releasing agonist for in vitro fertilisation: superiority of human chorionic gonadotrophn over oral progesterone. Fertil Steril 1990; 53:490–494.
48. Claman P, Domingo M, Leader A. Luteal phase support in in-vitro fertilisation using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone. Hum Reprod 1992; 7:487–489.
49. Sealey JE, McCord D, Taufield PA, Ales SA, Laragh JH. Plasma prorenin in first-trimester pregnancy: relationship to changes in human chorionic gonadotropin. Am J Obstet Gynecol 1985; 153:514–519.
50. Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 1995; 10:1355–1358.
51. Mehta N, Modi N. ACE inhibitors in pregnancy. Lancet 1989; 2:96.
52. Broughton, Pipkin F, Symonds EM, Turner SR. The effect of SQ 14,225 (Captopril) upon mother and fetus in the chronically-cannulated ewe and in the pregnant rabbit. J Physiol 1982; 323:415–422.
53. Pellicer A, Palumbo A, DeCemey AH, Naftolin F. Blockage of ovulation by an angiotensin antagonist. Science 1993; 240:1660–1661.
54. Morris RS, Paulson RJ, Lindheim SR, Legro RS, Lobo RA, Sauer MV. Angiotensin-converting enzyme inhibition reverses luteal phase steroid production in oocyte donors. Fertil Steril 1995; 63:854–858.
55. Rizk B. Ovarian hyperstimulation syndrome. In: Brinsden PR, Rainsbury PA, editors. A Textbook of In Vitro Fertilization and Assisted Reproduction. Camforth: Parthenon Publishing Group, 1992: 369–384.
56. Tan S-L, Balen A, Hussein E, Campbell S, Jacobs HS. The use of glucocorticoids for the prevention of ovarian hyperstimulation syndrome: a prospective randomized study. Fertil Sreril 1992; 58:378–383.
57. McClelland DBL. Human albumin solutions. In: Contreras, M, editors. ABC of Transfusions. London: BMJ Publishing Group, 1992: 35–40.
58. Rappaport SI. Blood and the plasma proteins: functions and composition of blood. In: West JB, editor. Best and Taylor’s Physiological Basis of Medical Practice. London: Williams and Wilkens, 1985:339–340.
59. Asch RH, Ivery G, Goldsman M, Frederick JL, Stone SC, Balmaceda JP. The use of intravenous albumin in patients at high risk for ovarian hyperstimulation syndrome. Hum Reprod 1993; 7:1015–1020.
60. Shalev E, Giladi Y, Matilsky M, Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilisation patients receiving intravenous albumin: a prospective study. Hum Reprod 1995; 10:1373–1376.
61. Goldsman MP, Balmaceda JP, Stone SC, Frederick JL, Kettel M, Asch RH. Use of albumin in the prevention of OHSS. Abstract presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, 1995.
62. Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in-vitro fertilisation program: a prospective, randomized, placebo controlled study. Fertil Steril 1994; 62: 137–142.
63. Ng E, Leader A, Claman P, Domingo M, Spence JEH. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 1995; 10: 807–810.
64. Lyons CAD, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792–799.